查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863430

細胞和基因治療藥物輸送裝置市場（按裝置類型、最終用戶、產品類型、治療方法和分銷管道分類）—2025-2032年全球預測

Cell & Gene Therapy Drug Delivery Devices Market by Device Type, End User, Product Type, Therapy Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞和基因治療藥物輸送裝置市場將成長至 25.7 億美元，複合年成長率為 10.29%。

關鍵市場統計數據
基準年 2024 11.7億美元
預計年份：2025年 12.9億美元
預測年份 2032 25.7億美元
複合年成長率 (%) 10.29%

一篇具有前瞻性的介紹性文章，概述了影響先進生物製藥遞送裝置策略的技術、臨床和監管方面的必要因素。

先進生物製藥與精準給藥裝置的融合正在重塑臨床醫生和醫療系統應對複雜治療方法的方式。裝置工程、材料科學和連接技術的最新創新為提高細胞和基因療法的給藥精度、患者依從性和安全性創造了新的機會。同時，涉及活細胞和基因載體的臨床項目對裝置的兼容性、低溫運輸物流和無菌給藥提出了嚴格的要求，迫使人們重新評估產品設計和操作流程。

產品開發、臨床營運和商業策略的相關人員如今面臨雙重挑戰：既要整合能夠最大限度減輕終端用戶負擔並保持治療效果的給藥技術，又要應對日益嚴格的聯合產品評估監管要求。這種情況使得工程師、轉化科學家和監管專家需要在研發週期的早期階段合作，多學科協作成為成功的關鍵因素。因此，那些優先考慮整合設備和療法開發、完善人體工學設計以及清晰監管流程的機構，更有利於加速臨床應用並擴大治療方案的覆蓋範圍。

全面審視醫療器材技術、分散式醫療和監管融合等領域的關鍵變革趨勢，這些趨勢正在重新定義治療提供方式。

由於治療複雜性、以患者為中心的護理模式以及數位健康整合的同步發展，細胞和基因治療遞送設備的格局正在經歷變革性變化。治療研發人員越來越關注微創給藥和門診管理，這促使醫療設備製造商開發創新產品，以減少對醫療機構的依賴，例如自動注射器、無針注射器、微流體系統和穿戴式輸注平台。同時，分散式醫療的趨勢正在加速發展，推動了對用於敏感生物製藥的醫療設備的投資增加，這些器材能夠在確保監管鍊和環境控制的同時，實現便捷的居家使用。

同時，為了滿足個人化治療和小批量治療方法的需求，生產製造和供應鏈正變得日益複雜。微流體裝置和模組化輸注系統能夠實現細胞產品的局部處理和即時操作，目前正在研究中，預計將縮短從採集到操作和給藥的關鍵時間。監管機構正在調整指導方針，以應對組合產品以及醫療設備和生物製藥的交叉領域，並鼓勵申辦方和監管機構之間進行更積極的互動。此外，設備中正在整合數位連接和遠端監測功能，提供即時依從性和安全性數據，以支援治療通訊協定的迭代改進和上市後監測。總而言之，這些變化既帶來了機遇，也帶來了挑戰，要求各組織採用整合的開發路徑，並與相關人員密切合作，才能充分利用不斷變化的環境。

2025年前累積關稅對配送系統採購、供應商選擇和製造業韌性的影響策略評估

新關稅的實施對進口醫療組件和成品醫療設備造成了顯著影響，對細胞和基因治療輸送系統的供應鏈帶來了巨大壓力。累積關稅將持續到2025年，導致用於自動注射器、輸液幫浦和一次性拋棄式產品的某些上游原料、特殊聚合物和精密組件的成本上升。因此，我們的採購部門正在審查供應商組合，探索替代來源，並重新評估總到岸成本模型，以確保專案的可行性和價格透明度。

為此，許多製造商採取了供應商多元化和盡可能將生產外包到近岸地區的雙管齊下的策略，以最大限度地降低關稅風險並縮短關鍵零件的前置作業時間。這些方法各有利弊。生產轉移可以降低關稅風險，但可能需要資本投資、員工培訓以及對新品質系統的檢驗。此外，關稅導致的成本增加也影響了契約製造協議的談判和長期供應契約，因此，明確的商業條款、風險分擔機制和緊急時應對計畫顯得尤為重要。

監管合規性和可追溯性要求增加了複雜性，因為隨著採購來源的變化，醫療設備申請需要檢驗和更新。因此，各組織必須採用基於情境的採購計劃，將關稅敏感性、供應商資格認證時間表和監管影響評估納入考量，以確保供應的連續性和治療的可及性。

將設備類型、最終用戶、產品形式、治療方法和通路與戰略產品決策聯繫起來的詳細細分分析

要使產品開發和商業化策略與臨床和營運實際情況相符，對細分市場動態的深入理解至關重要。依設備類型分析，競爭格局涵蓋自動注射器、植入式幫浦、輸液幫浦、微流體裝置、無針注射器、預填充式注射器和傳統注射器，每種產品在精準給藥、便攜性和監管複雜性之間各有重點。同樣，按最終用戶分析也揭示了診所、居家醫療機構、醫院和專科護理中心的不同需求。醫院需要整合的設備生態系統和高通量可靠性，而居家醫療和專科護理中心則更注重易用性、緊湊的外形尺寸和遠端監控功能。

產品類型細分突顯了具有生命週期服務的可重複使用系統與一次性拋棄式之間的區別，後者簡化了滅菌管理並降低了交叉污染風險，指南維護基礎設施和單位經濟效益方面的選擇。治療方法區分了細胞療法和基因療法。在細胞療法中，CAR-T 療法、樹突細胞療法和幹細胞療法各自對操作、給藥途徑和時間限制各有不同；而基因療法則區分了非病毒載體和病毒載體策略，這會影響到控制措施、給藥準確性和監管申報結構。分銷管道的差異——醫院藥房、線上藥房和零售藥房——進一步細分，其中線上藥房分為通訊模式和傳統線上模式，零售藥房分為連鎖店和獨立門市。這突顯了不同管道在物流、低溫運輸要求和照護端協調方面的差異。整合這些細分觀點有助於制定有針對性的產品藍圖和分銷策略，從而反映實際應用情境和相關人員的偏好。

本文從實際角度檢驗了區域法規環境、基礎設施建設和醫療服務模式如何影響醫療設備的採用和普及。

區域趨勢對醫療器材策略、監管互動和商業化執行有著深遠的影響。有效的規劃需要針對不同區域採取差異化的方法。在美洲，臨床試驗活動、集中化的卓越中心以及不斷完善的醫保報銷環境，都為創新醫療解決方案的快速普及提供了支持。然而，清晰的報銷路徑和支付方參與對於更廣泛的應用仍然至關重要。歐洲、中東和非洲地區（EMEA）的監管環境各不相同，各國醫療設備框架和採購模式的差異，要求制定適應性強的監管策略和區域性的價值提案。然而，在某些司法管轄區，集中採購和與公共醫療系統合作蘊藏著巨大的機會。亞太地區正在經歷快速發展的創新中心、不斷完善的醫院基礎設施以及對分散式醫療模式日益成長的關注，但相關人員必須克服因市場而異的監管時間表和物流挑戰。

無論在哪個地區，在專業中心之外使用複雜生物製藥製劑的可行性取決於低溫運輸基礎設施的成熟度、醫療衛生人力能力以及患者獲取途徑的完善程度。因此，企業應優先考慮針對特定地區的證據產生、為臨床醫生和看護者客製化的培訓項目，以及與當地藥房和醫院採購慣例相符的經銷夥伴。制定一項結合全球標準和本地適應性的協調一致的區域策略，對於在確保品質和患者安全的同時擴大先進療法的應用規模至關重要。

深入剖析製造商、創新者和服務供應商如何調整營運和合作關係，以加速醫療設備輔助治療方法的普及應用。

主要企業的行動正朝著幾個戰略要務匯聚，這些要務將影響它們在給藥裝置領域的競爭地位。成熟的醫療技術公司正利用其深厚的監管經驗、生產規模和分銷網路，拓展至專業給藥系統領域，並經常與治療方法開發商尋求合作和授權，以打造整合組合產品。同時，敏捷的Start-Ups和裝置創新者正透過平台技術實現差異化，例如模組化注射架構、緊湊型微流體處理器和感測器驅動的自動注射器，這些技術能夠解決特定的臨床難題，並實現人體工學和連接功能的快速改進。

合約研發生產機構 (CDMO) 提供無塵室設施、可擴展的組裝和滅菌服務，在一次性使用產品和複雜組合產品領域發揮日益重要的作用。同時，專注於低溫運輸物流和檢驗的運輸系統的公司正成為治療方法申辦方尋求可預測的交付時間和溫度敏感型生物製藥可追溯性的策略合作夥伴。在整個生態系統中，成功的企業正在採用協作式市場推廣策略，投資早期監管對話，並優先進行嚴格的人體工學研究，以降低實施風險。競爭優勢越來越依賴於展現產品在實際應用中的可靠性、與臨床工作流程的互通性以及上市後資料收集能力，以支援持續的安全性和效能監測。

為醫療設備開發商和治療方法贊助商提供切實可行的、優先排序的策略建議，以協調創新、供應鏈韌性和監管準備。

為了最大限度地發揮先進生物製劑的治療和營運價值，產業領導者應採取將器械創新與臨床工作流程、監管策略和商業性執行相結合的方法。首先，在設計過程早期就應納入人體工學和臨床醫生參與，以確保器械滿足所有給藥環境（包括醫院、專科中心、診所和家庭配送）的實際限制。這種早期調整可以減少返工並加快監管核准。其次，應建立多元化的供應鏈，利用合格的二級供應商和關鍵零件的近岸外包選項，以在降低關稅和前置作業時間風險的同時，保持嚴格的品管。

第三，組成跨職能團隊，成員包括監管、轉化研究、生產和商業等相關人員，以指導聯合用藥產品的核准途徑，並制定上市後監測和真實世界資料收集計畫。第四，投資數位化（互聯互通、遠端監測和分析），以提高病患依從性，及早發現安全訊號，並向支付者和醫療服務提供者展現價值。最後，制定靈活的分銷策略，以適應不同管道的差異，包括醫院藥房、線上和通訊模式、連鎖和獨立零售網路以及門診機構。透過實施這些措施，企業可以減少商業化阻力，支持以患者為中心的醫療模式，並建立適應不斷變化的治療模式的彈性運作體系。

透明的混合方法研究結合了直接的專家對話和二手證據綜合，確保了研究結果的嚴謹性和可操作性。

本研究採用混合方法，將質性專家見解與嚴謹的二次檢驗結合，以得出可操作的結論。主要數據包括對醫療設備工程師、臨床研究人員、藥屋主任和供應鏈經理的深入訪談，以及與監管專家的結構化諮詢，以了解應用和上市後要求。這些相關人員的對話旨在捕捉有關醫療設備可用性、病毒和非病毒載體控制需求以及醫院、診所、專科護理中心和居家醫療環境中實際工作流程限制等方面的經驗細節。

二次分析利用已發布的監管指南、同行評審文獻、臨床試驗註冊資訊和供應商技術資料表，以檢驗的證據支持研究結果。此外，它還整合了具有代表性的醫療設備和治療方法組合的案例研究，以闡明設計選擇、人體工學迭代和物流解決方案。資料三角驗證確保結論得到資訊來源支持，並透過記錄的假設、訪談指南和檢驗查核點，使調查方法透明化。此方法始終強調可重複性和相關人員的檢驗，確保研究結果反映實際操作情況，並為研發、監管和商業等各個環節的實際決策提供依據。

簡潔扼要的結論總結了設備創新、營運韌性和相關人員之間的協作將如何決定醫療服務的成功交付。

整體結論顯而易見：細胞和基因療法的成功應用，不僅取決於生物治療方法本身，也取決於遞送系統的設計和物流協調。設備技術的創新，加上數位化連接和自適應分銷模式的進步，正在加速複雜治療方法的去中心化，同時也提高了對人為因素、低溫運輸管理和監管協調的要求。同時，關稅政策的波動和區域基礎設施的差異等外部因素，也要求制定積極主動的供應鏈策略和在地化的商業化方案。

儘早整合跨職能團隊、優先考慮以使用者為中心的迭代設計並積極與監管機構溝通的組織，將能夠降低技術和商業性風險。此外，有效整合設備和治療方法需要製造商、合約合作夥伴、物流專家和醫療服務提供者等日益壯大的生態系統之間的協作。最終，能否實現可擴展、安全且以患者為中心的先進生物製劑交付，將取決於相關人員在產品生命週期內協調技術卓越性、營運韌性和循證實踐的能力。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合用於可擴展CAR-T細胞生產的封閉式自動化微流體系統
  • 開發一種穿戴式生物感測器設備，實現對基因治療遞送的即時監測
  • 皮膚科局部基因編輯中無針電穿孔貼片的應用
  • 用於局部細胞和基因傳遞的可生物分解水凝膠支架植入的研究進展
  • 引入人工智慧驅動的設計軟體來最佳化病毒載體，以提高基因治療的安全性
  • 攜帶式冷凍保存裝置的出現，為分散式、按需CAR-T細胞和幹細胞保存提供了可能。
  • 擴展3D生物列印系統，以實現直接原位組織工程和標靶基因遞送
  • 利用微針陣列貼片實現基於 CRISPR 的基因療法的無痛皮內遞送

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按設備類型分類的細胞和基因治療藥物傳輸設備市場

  • 自動注射器
  • 植入式幫浦
  • 點滴幫浦
  • 微流體控裝置
  • 無針注射器
  • 預填充式注射器
  • 注射器

9. 按最終用戶分類的細胞和基因治療藥物傳輸設備市場

  • 診所
  • 居家醫療
  • 醫院
  • 專業醫療機構

第10章：按產品類型分類的細胞和基因治療藥物輸送裝置市場

  • 可重複使用的
  • 一次使用

第11章 細胞與基因療法藥物傳遞裝置市場（依治療方法）

  • 細胞療法
    • CAR-T療法
    • 樹突細胞療法
    • 幹細胞療法
  • 基因治療
    • 非病毒載體
    • 病毒載體

第12章 細胞與基因治療藥物輸送裝置市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
    • 通訊藥房
    • 傳統藥房及網上藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第13章 細胞與基因治療藥物傳遞裝置市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 細胞與基因治療藥物傳遞裝置市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國細胞及基因治療藥物傳遞裝置市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Becton, Dickinson and Company
    • Terumo Corporation
    • B. Braun Melsungen AG
    • ICU Medical, Inc.
    • West Pharmaceutical Services, Inc.
    • Gerresheimer AG
    • Ypsomed Holding AG
    • Catalent, Inc.
    • Fresenius SE & Co. KGaA
    • MaxCyte, Inc.
Product Code: MRR-5C6F41F5AF95

The Cell & Gene Therapy Drug Delivery Devices Market is projected to grow by USD 2.57 billion at a CAGR of 10.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.17 billion
Estimated Year [2025] USD 1.29 billion
Forecast Year [2032] USD 2.57 billion
CAGR (%) 10.29%

A forward-looking introduction that frames the technical, clinical, and regulatory imperatives shaping delivery device strategies for advanced biologics

The convergence of advanced biologics and precision delivery devices is reshaping how clinicians and healthcare systems approach complex therapies. Recent innovations in device engineering, materials science, and connectivity have created new opportunities to improve dosing accuracy, patient adherence, and safety for cell and gene therapies. At the same time, clinical program requirements for handling living cells and genetic vectors impose exacting constraints on device compatibility, cold chain logistics, and aseptic administration, demanding a fresh evaluation of product design and operational workflows.

Stakeholders across product development, clinical operations, and commercial strategy now face a bifurcated challenge: integrate enabling delivery technologies that preserve therapeutic integrity while minimizing complexity for end users, and simultaneously navigate increasingly stringent regulatory expectations for combination product evaluation. These dynamics have elevated cross-disciplinary collaboration as a critical success factor, with engineers, translational scientists, and regulatory experts needing to converge earlier in development cycles. As a result, organizations that prioritize integrated device-therapy development, robust human factors engineering, and clear regulatory engagement pathways are better positioned to advance clinical adoption and scale treatment delivery.

A comprehensive exploration of the major transformative trends in device technology, decentralized care, and regulatory convergence redefining therapeutic delivery

The landscape for cell and gene therapy delivery devices is undergoing transformative shifts driven by parallel advances in therapy complexity, patient-centric care models, and digital health integration. Therapy developers increasingly prioritize minimally invasive delivery and outpatient administration, prompting device makers to innovate with autoinjectors, needle-free injectors, microfluidic systems, and wearable infusion platforms that reduce clinic dependency. At the same time, the trend toward decentralized care has accelerated investment in devices that are intuitive for home use while maintaining chain-of-custody and environmental controls for sensitive biologics.

Concurrently, manufacturing and supply chain sophistication are rising to meet the demands of personalized and batch-limited therapies. Microfluidic devices and modular infusion systems are being explored to enable localized processing and point-of-care manipulation of cell products, which could shorten critical timelines between harvest, manipulation, and delivery. Regulatory authorities are adapting guidance to address combination products and the intersection of device and biologic review, which is prompting more proactive engagement between sponsors and regulators. Moreover, digital connectivity and remote monitoring capabilities are being embedded into devices to provide real-time adherence and safety data, supporting iterative improvements in therapy protocols and post-market surveillance. Taken together, these shifts create both opportunities and complexities, and organizations must adopt integrated development pathways and robust stakeholder collaboration to capitalize on the evolving environment.

A strategic assessment of how cumulative tariff measures through 2025 are reshaping procurement, sourcing, and manufacturing resilience for delivery systems

The introduction of new tariff measures affecting imported medical components and finished devices is exerting measurable pressure on the supply chains that underpin cell and gene therapy delivery systems. Cumulative tariff actions enacted through 2025 have increased costs for certain upstream raw materials, specialized polymers, and precision components used in autoinjectors, infusion pumps, and single-use disposables. As a consequence, procurement teams are recalibrating supplier portfolios, exploring alternative sources, and reassessing total landed cost models to maintain program viability and pricing transparency.

In response, many manufacturers have initiated dual strategies of supplier diversification and nearshoring where feasible, seeking to minimize exposure to tariff volatility and reduce lead times for critical components. These approaches lead to trade-offs: relocating production can reduce tariff risk but may require capital investment, workforce training, and new quality system validations. Additionally, tariff-driven cost increases have implications for contract manufacturing negotiations and long-term supply agreements, elevating the importance of clear commercial terms, risk-sharing structures, and contingency planning.

Regulatory compliance and traceability requirements further complicate mitigation efforts, as sourcing alterations necessitate revalidation and potential device submission updates. Therefore, organizations must adopt scenario-based procurement planning that integrates tariff sensitivity, supplier qualification timelines, and regulatory impact assessments to preserve continuity of supply and maintain treatment accessibility.

A detailed set of segmentation insights linking device types, end users, product formats, therapy modalities, and distribution pathways to strategic product decisions

A nuanced understanding of segmentation dynamics is essential for aligning product development and commercialization strategies with clinical and operational realities. When studied by device type, the competitive landscape spans autoinjectors, implantable pumps, infusion pumps, microfluidic devices, needle-free injectors, pre-filled syringes, and conventional syringes, each offering distinct trade-offs between precision dosing, portability, and regulatory complexity. Likewise, analysis by end user highlights divergent needs across clinics, homecare settings, hospitals, and specialty centers; hospitals demand integrated device ecosystems and high-throughput reliability, while homecare and specialty centers prioritize ease of use, compact form factors, and remote monitoring capabilities.

Product type segmentation emphasizes the contrast between reusable systems that support lifecycle servicing and single-use disposables that simplify sterility and reduce cross-contamination risk, informing choices around maintenance infrastructure and unit economics. Therapy type segmentation divides the space into cell therapy and gene therapy; within cell therapy, CAR-T therapies, dendritic cell approaches, and stem cell treatments each impose unique handling, administration route, and timing constraints, whereas gene therapy pathways differentiate non-viral vector and viral vector strategies with implications for containment, dosing accuracy, and regulatory dossier composition. Distribution channel distinctions among hospital pharmacy, online pharmacy, and retail pharmacy, with online pharmacy further split into mail order and traditional online models and retail pharmacy further differentiated between chain and independent outlets, underscore how logistics, cold chain requirements, and point-of-care coordination vary by pathway. Integrating these segmentation perspectives enables targeted product roadmaps and distribution strategies that reflect real-world use cases and stakeholder preferences.

A pragmatic examination of how regional regulatory environments, infrastructure maturity, and healthcare delivery models influence device deployment and adoption

Regional dynamics exert a profound influence on device strategy, regulatory engagement, and commercialization execution, and effective planning requires a regionally differentiated approach. In the Americas, clinical trial activity, concentrated centers of excellence, and a progressive reimbursement environment support rapid adoption of novel delivery solutions, while reimbursement pathway clarity and payer engagement remain critical for broader uptake. Europe, the Middle East & Africa present a heterogeneous regulatory landscape, where varying national device frameworks and divergent procurement models necessitate adaptive regulatory strategies and localized value propositions; this region also offers strong opportunities for centralized procurement and collaborations with public health systems in certain jurisdictions. Asia-Pacific combines rapid innovation hubs, expanding hospital infrastructure, and an increasing focus on decentralized care models, but stakeholders must navigate diverse regulatory timelines and logistics challenges across markets.

Across regions, cold chain infrastructure maturity, healthcare workforce capacity, and patient access models shape the practical viability of complex biologic administrations outside specialized centers. Therefore, companies must prioritize region-specific evidence generation, tailored training programs for clinicians and caregivers, and distribution partnerships that align with local pharmacy and hospital procurement practices. Coordinated regional strategies that balance global standards with local adaptability will be essential to scale advanced therapies while ensuring consistent quality and patient safety.

An incisive look at how manufacturers, innovators, and service providers are aligning operations and partnerships to accelerate device-enabled therapy adoption

Key corporate behaviors are converging around several strategic imperatives that influence competitive positioning in the delivery device segment. Established medtech firms are leveraging deep regulatory experience, manufacturing scale, and distribution networks to expand into specialty delivery systems, frequently pursuing partnerships or licensing arrangements with therapy developers to create integrated combination products. At the same time, agile startups and device innovators are differentiating through platform technologies-such as modular infusion architectures, compact microfluidic processors, and sensor-enabled autoinjectors-that address specific clinical pain points and enable faster iteration of human factors and connectivity features.

Contract development and manufacturing organizations play an increasingly central role, offering clean-room capacity, scalable assembly, and sterilization services that are essential for single-use disposables and complex combination products. Meanwhile, companies specializing in cold chain logistics and validated transport systems are becoming strategic partners for therapy sponsors seeking predictable delivery windows and traceability for temperature-sensitive biologics. Across the ecosystem, successful players adopt collaborative go-to-market strategies, invest in early regulatory dialogue, and prioritize rigorous human factors studies to de-risk adoption. Competitive differentiation increasingly hinges on the ability to demonstrate real-world reliability, interoperability with clinical workflows, and post-market data collection capabilities that support ongoing safety and performance monitoring.

A practical and prioritized set of strategic recommendations for device developers and therapy sponsors to align innovation, supply resilience, and regulatory readiness

Industry leaders should pursue an integrated approach that aligns device innovation with clinical workflow, regulatory strategy, and commercial execution to capture the full therapeutic and operational value of advanced biologics. First, embed human factors and clinician engagement early in the design process to ensure devices meet practical constraints of administration environments, whether in a hospital, specialty center, clinic, or the home. This early alignment reduces rework and accelerates regulatory acceptance. Second, cultivate diversified supply chains with qualified secondary suppliers and nearshoring options for critical components to mitigate tariff exposure and lead-time risk while maintaining robust quality governance.

Third, establish cross-functional teams that include regulatory, translational, manufacturing, and commercial stakeholders to navigate combination product pathways and to plan for post-market surveillance and real-world evidence collection. Fourth, invest in digital enablement-connectivity, remote monitoring, and analytics-to enhance adherence, detect early safety signals, and provide evidence of value to payers and providers. Finally, develop flexible distribution strategies that reflect differences across hospital pharmacies, online and mail order models, chain and independent retail networks, and outpatient care settings. By implementing these actions, organizations can reduce commercialization friction, support patient-centric care models, and build resilient operations that accommodate evolving therapy paradigms.

A transparent mixed-methods research approach combining primary expert engagements and secondary evidence synthesis to ensure rigorous and actionable insights

This research employs a mixed-methods approach that synthesizes qualitative expert insight with rigorous secondary validation to produce actionable findings. Primary inputs include in-depth interviews with device engineers, clinical investigators, pharmacy directors, and supply chain executives, combined with structured consultations with regulatory specialists to understand submission and post-market requirements. These stakeholder engagements are designed to capture experiential nuances around device usability, containment needs for viral and non-viral vectors, and real-world workflow constraints across hospitals, clinics, specialty centers, and homecare environments.

Secondary analysis draws on publicly available regulatory guidance, peer-reviewed literature, clinical trial registries, and supplier technical datasheets to ground findings in verifiable evidence. The research also integrates case study reviews of representative device-therapy pairings to illustrate design choices, human factors iterations, and logistics solutions. Data triangulation ensures conclusions are corroborated across multiple sources, and methodological transparency is maintained through documented assumptions, interview guides, and validation checkpoints. Throughout, the approach emphasizes reproducibility and stakeholder validation to ensure that insights reflect operational realities and inform practical decision-making across development, regulatory, and commercial functions.

A concise conclusion synthesizing how device innovation, operational resilience, and stakeholder collaboration determine successful therapy delivery outcomes

The cumulative narrative is clear: successful deployment of cell and gene therapies depends as much on delivery system design and logistical orchestration as it does on the biological modality itself. Innovations in device technology, coupled with digital connectivity and adaptive distribution models, are enabling broader decentralization of complex therapies while elevating requirements for human factors, cold chain management, and regulatory coordination. At the same time, external forces such as tariff policy shifts and regional infrastructure disparities necessitate proactive supply chain strategies and localized commercialization approaches.

Organizations that integrate cross-functional teams early, prioritize iterative user-centered design, and engage regulators proactively will reduce technical and commercial risk. Moreover, the effective pairing of device and therapy demands collaboration across a growing ecosystem of manufacturers, contract partners, logistics specialists, and healthcare providers. Ultimately, the path to scalable, safe, and patient-centric delivery of advanced biologics will be determined by the ability of stakeholders to harmonize engineering excellence, operational resilience, and evidence generation throughout the product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of closed automated microfluidic systems for scalable CAR-T cell manufacturing
  • 5.2. Development of wearable biosensor devices for real-time monitoring of gene therapy delivery
  • 5.3. Adoption of needle-free electroporation patches for in situ gene editing in dermatological applications
  • 5.4. Advancement of biodegradable hydrogel scaffold implants for localized cell and gene delivery
  • 5.5. Implementation of AI-driven design software in viral vector optimization for improved gene therapy safety
  • 5.6. Emergence of portable cryopreservation units for decentralized on-demand CAR-T and stem cell storage
  • 5.7. Expansion of 3D bioprinter systems for direct in situ tissue engineering and targeted gene incorporation
  • 5.8. Use of microneedle array patches for pain-free intradermal delivery of CRISPR-based gene therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Drug Delivery Devices Market, by Device Type

  • 8.1. Autoinjector
  • 8.2. Implantable Pump
  • 8.3. Infusion Pump
  • 8.4. Microfluidic Device
  • 8.5. Needle-Free Injector
  • 8.6. Pre-Filled Syringe
  • 8.7. Syringe

9. Cell & Gene Therapy Drug Delivery Devices Market, by End User

  • 9.1. Clinic
  • 9.2. Homecare
  • 9.3. Hospital
  • 9.4. Specialty Center

10. Cell & Gene Therapy Drug Delivery Devices Market, by Product Type

  • 10.1. Reusable
  • 10.2. Single Use

11. Cell & Gene Therapy Drug Delivery Devices Market, by Therapy Type

  • 11.1. Cell Therapy
    • 11.1.1. CAR-T Therapy
    • 11.1.2. Dendritic Cell Therapy
    • 11.1.3. Stem Cell Therapy
  • 11.2. Gene Therapy
    • 11.2.1. Non-Viral Vector
    • 11.2.2. Viral Vector

12. Cell & Gene Therapy Drug Delivery Devices Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
    • 12.2.1. Mail Order Pharmacy
    • 12.2.2. Traditional Online Pharmacy
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. Cell & Gene Therapy Drug Delivery Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Drug Delivery Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Drug Delivery Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Becton, Dickinson and Company
    • 16.3.2. Terumo Corporation
    • 16.3.3. B. Braun Melsungen AG
    • 16.3.4. ICU Medical, Inc.
    • 16.3.5. West Pharmaceutical Services, Inc.
    • 16.3.6. Gerresheimer AG
    • 16.3.7. Ypsomed Holding AG
    • 16.3.8. Catalent, Inc.
    • 16.3.9. Fresenius SE & Co. KGaA
    • 16.3.10. MaxCyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SI